<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=896170837107954&amp;ev=PageView&amp;noscript=1">

Back to Press Releases

NeoTract Convenes Leading Urologists for Summit on Treating Benign Prostatic Hyperplasia (BPH) and Lower Urinary Tract Symptoms


PLEASANTON, Calif. – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, recently hosted more than 60 urologists from around the country to review clinical data and share best practices for using the UroLift® System to improve the care of patients with enlarged prostate, or benign prostatic hyperplasia (BPH). Highlights from the meeting included robust data presentations and the designation of three new UroLift Centers of Excellence from Jamestown, New York; Pittsburgh, Penn., and Fullerton, Calif.

UroLift Centers of Excellence are recognized for completing extensive training and demonstrating high success in advancing patient outcomes in men with lower urinary tract symptoms. Currently, eight physician practices across the nation have the experience and outcomes to have earned this distinction.

“I am honored and humbled to have my practice named as a UroLift Center of Excellence,” said Peter Walter, M.D., of Western New York Urology Associates in Jamestown, NY. “After treating nearly 200 patients, I have seen firsthand the dramatic benefits and quality of life improvements we can offer to men who undergo the UroLift procedure. I believe it is important to continue to share our personal clinical experiences and data with peers so we can look to eventually eliminate the burden of BPH.”

Over the course of the two-day summit, podium presentations reviewed data and case presentations. Claus Roehrborn, M.D., professor and chairman of the Department of Urology, UT Southwestern in Dallas, opened the second day of talks with a new technology and clinical data review. Dr. Roehrborn serves as co-principal investigator for the pivotal, randomized L.I.F.T. IDE study.

 “The UroLift clinical publication record is flawless,” said Dr. Roehrborn. “Every patient treated under a clinical protocol appears in at least one peer-reviewed publication.  The outcomes from the numerous studies are consistent, demonstrating rapid relief within two weeks and sustained improvement in symptoms, quality of life and urinary flow through four years1.”

“We are pleased with the large number of attendees at our first Summit,” said Dave Amerson, president and CEO, NeoTract, Inc. “We’re very fortunate to work with such a dedicated, talented group of physicians who take time out of their busy schedules to learn from us and from each other how to achieve the best possible outcomes for their patients.”

More than 37 million men in the United States are affected by BPH, which occurs with advancing age when the prostate gland that surrounds the male urethra becomes enlarged and begins to obstruct the urinary system. Symptoms of BPH often include sleepless nights and urinary problems, and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra.

About the UroLift System

The FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia and Canada. Learn more at www.UroLift.com.

About NeoTract

NeoTract, Inc. is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. The company’s initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.

# # #

Media Contact:
Nicole Osmer

1 Roehrborn, 2016 Urology Clinics

MAC00413-01 Rev A